The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.

Inclusion Criteria:

• Histological or cytological confirmation of an advanced solid malignant tumour (or lymphoma Part A only)
• Cancer which is refractory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria) can be recruited to Part A
• Evidence of post-menopausal status or negative urine/serum pregnancy test for pre-menopausal female patients

Exclusion Criteria:

• Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug.
• Patients with abnormal fasting glucose, have type I or II Diabetes or have uncontrolled blood fats and cholesterol
• Patients with a history of neurological disease, peripheral or central neuropathy, brain metastases or family history of myopathy are excluded
• Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions